Tyrosine kinase inhibitors of VEGF receptors : Clinical issues and remaining questions

Frontiers in Bioscience

Volumn 14, Issue 6, 2009, Pages 2248-2268

  Van Cruijsen, Hester ^a   Van Der Veldt, Astrid ^a   Hoekman, Klaas ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Cancer; Efficacy; Evaluation; Pharmacology; Response; Review; Therapy; Toxicity; Tyrosine kinase inhibitors; VEGFR

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

DRUG ANTAGONISM; HUMAN; REVIEW;

ANGIOGENESIS INHIBITORS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 62449192134     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3377     Document Type: Article

References (206)

1. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat Med, 6, 389-95 (2000). (Pubitemid 30208155)
2. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25, 581-611 (2004). (Pubitemid 39099316)
3. Benjamin, L. E., D. Golijanin, A. Itin, D. Pode & E. Keshet: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest, 103, 159-65 (1999). (Pubitemid 29053133)
4. Dvorak, H. F., L. F. Brown, M. Detmar & A. M. Dvorak: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, 1029-39 (1995).
5. Jain, R. K. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med, 7, 987-9 (2001). (Pubitemid 32937367)
6. Houck, K. A., N. Ferrara, J. Winer, G. Cachianes, B. Li & D. W. Leung: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol, 5, 1806-14 (1991).
7. Houck, K. A., D. W. Leung, A. M. Rowland, J. Winer & N. Ferrara: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem, 267, 26031-7 (1992). (Pubitemid 23014012)
8. Bergers, G., R. Brekken, G. McMahon, T. H. Vu, T. Itoh, K. Tamaki, K. Tanzawa, P. Thorpe, S. Itohara, Z. Werb & D. Hanahan: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol, 2, 737-44 (2000).
9. Siemeister, G., K. Weindel, K. Mohrs, B. Barleon, G. Martiny-Baron & D. Marme: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res, 56, 2299-301 (1996). (Pubitemid 26154077)
10. Dor, Y., R. Porat, & E. Keshet: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol, 280, C1367-C1374 (2001). (Pubitemid 32553191)
11. Zundel, W., C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A. R. Gottschalk, H. E. Ryan, R. S. Johnson, A. B. Jefferson, D. Stokoe & A. J. Giaccia: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev, 14, 391-6 (2000). (Pubitemid 30131884)
12. Rak, J., Y. Mitsuhashi, L. Bayko, J. Filmus, S. Shirasawa, T. Sasazuki & R. S. Kerbel: Mutant ras Oncogenes Upregulate VEGF/VPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis. Cancer Res, 55, 4575-80 (1995).
13. Grugel, S., G. Finkenzeller, K. Weindel, B. Barleon & D. Marme: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem, 270, 25915-9 (1995).
14. Van Cruijsen, H., G. Giaccone & K. Hoekman: Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer, 117, 883-8 (2005). (Pubitemid 41688561)
15. Nauck, M., M. Roth, M. Tamm, O. Eickelberg, H. Wieland, P. Stulz & A. P. Perruchoud: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol, 16, 398-406 (1997). (Pubitemid 127497465)
16. Ito, T. K., G. Ishii, H. Chiba & A. Ochiai: The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene, 26, 7194-203 (2007). (Pubitemid 350085324)
17. Yu, J. L. & J. W. Rak: Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res, 5, 83-8 (2003). (Pubitemid 36348101)
18. Potgens, A. J., N. H. Lubsen, M. C. van Altena, R. Vermeulen, A. Bakker, J. G. Schoenmakers, D. J. Ruiter & R. M. de Waal: Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem, 269, 32879-85 (1994).
19. Bielenberg, D. R. & M. Klagsbrun: Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev, 26, 421-31 (2007). (Pubitemid 350115126)
20. Betsholtz, C., L. Karlsson & P. Lindahl: Developmental roles of platelet-derived growth factors. Bioessays, 23, 494-507 (2001). (Pubitemid 32575610)
21. Alvarez, R. H., H. M. Kantarjian & J. E. Cortes: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc, 81, 1241-57 (2006). (Pubitemid 44316290)
22. Presta, M., P. Dell'Era, S. Mitola, E. Moroni, R. Ronca & M. Rusnati: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev, 16, 159-78 (2005). (Pubitemid 40616114)
23. Kim, K. J., B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, & N. Ferrara: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-4 (1993). (Pubitemid 23132159)
24. Millauer, B., L. K. Shawver, K. H. Plate, W. Risau & A. Ullrich: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367, 576-9 (1994).
25. Willett, C. G., Y. Boucher, E. di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva, S. V. Kozin, M. Mino, K. S. Cohen, D. T. Scadden, A. C. Hartford, A. J. Fischman, J. W. Clark, D. P. Ryan, A. X. Zhu, L. S. Blaszkowsky, H. X. Chen, P. C. Shellito, G. Y. Lauwers & R. K. Jain: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145-7 (2004). (Pubitemid 38524883)
26. Batchelor, T. T., A. G. Sorensen, E. di Tomaso, W. T. Zhang, D. G. Duda, K. S. Cohen, K. R. Kozak, D. P. Cahill, P. J. Chen, M. Zhu, M. Ancukiewicz, M. M. Mrugala, S. Plotkin, J. Drappatz, D. N. Louis, P. Ivy, D. T. Scadden, T. Benner, J. S. Loeffler, P. Y. Wen & R. K. Jain: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 11, 83-95 (2007). (Pubitemid 46075199)
27. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross & F. Kabbinavar: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42 (2004). (Pubitemid 38702844)
28. Motzer, R. J., T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, I. Chen, P. W. Bycott, C. M. Baum & R. A. Figlin: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24 (2007). (Pubitemid 46089672)
29. Escudier, B., T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A. A. Desai, F. Rolland, T. Demkow, T. E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov & R. M. Bukowski: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, 125-34 (2007). (Pubitemid 46089673)
30. Szczylik, C., T. Demkow, M. Staehler, F. Rolland, S. Negrier, T. E. Hutson, R. M. Bukowski, U. J. Scheuring, K. Burk & B. Escudier: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol (Meeting Abstracts), 25, 5025 (2007).
31. Rixe, O., R. M. Bukowski, M. D. Michaelson, G. Wilding, G. R. Hudes, O. Bolte, R. J. Motzer, P. Bycott, K. F. Liau, J. Freddo, P. C. Trask, S. Kim & B. I. Rini: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol, 8, 975-84 (2007). (Pubitemid 47629888)
32. Brugarolas, J. Renal-Cell Carcinoma - Molecular Pathways and Therapies. N Engl J Med, 356, 185-7 (2007). (Pubitemid 46089681)
33. Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen & S. A. Rosenberg: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349, 427-34 (2003). (Pubitemid 36910021)
34. Burstein, H. J., A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, C. M. Baum & K. D. Miller: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 26, 1810-6 (2008).
35. Socinski, M. A., S. Novello, J. R. Brahmer, R. Rosell, J. M. Sanchez, C. P. Belani, R. Govindan, J. N. Atkins, H. H. Gillenwater, C. Pallares, L. Tye, P. Selaru, R. C. Chao & G. V. Scagliotti: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol, 26, 650-6 (2008). (Pubitemid 351264362)
36. Chi, K. N., S. L. Ellard, S. J. Hotte, P. Czaykowski, M. Moore, J. D. Ruether, A. J. Schell, S. Taylor, C. Hansen, I. Gauthier, W. Walsh & L. Seymour: A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol, 19, 746-51 (2007).
37. Dahut, W. L., C. Scripture, E. Posadas, L. Jain, J. L. Gulley, P. M. Arlen, J. J. Wright, Y. Yu, L. Cao, S. M. Steinberg, J. B. Aragon-Ching, J. Venitz, E. Jones, C. C. Chen & W. D. Figg: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res, 14, 209-14 (2008). (Pubitemid 351377997)
38. Steinbild, S., K. Mross, A. Frost, R. Morant, S. Gillessen, C. Dittrich, D. Strumberg, A. Hochhaus, A. R. Hanauske, L. Edler, I. Burkholder & M. Scheulen: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer, 97, 1480-5 (2007). (Pubitemid 350175850)
39. Llovet, J., S. Ricci, V. Mazzaferro, P. Hilgard, J. Raoul, S. Zeuzem, M. Poulin-Costello, M. Moscovici, D. Voliotis, J. Bruix & for the SHARP Investigators Study Group: Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts), 25, LBA1 (2007).
40. Gupta, V., K. Puttaswamy, W. Lassoued, M. Redlinger, K. Ransone, K. Gold, W. Lee, V. LiVolsi, D. Fraker, S. Mandel & M. S. Brose: Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. J Clin Oncol (Meeting Abstracts), 25, 6019 (2007).
41. Cohen, E. E., E. E. Vokes, L. S. Rosen, M. S. Kies, A. A. Forastiere, F. P. Worden, M. A. Kane, K. F. Liau, D. R. Shalinsky & R. B. Cohen: A phase II study of axitinib (AG-013736 (AG)) in patients (pts) with advanced thyroid cancers. J Clin Oncol (Meeting Abstracts), 25, 6008 (2007).
42. Demetri, G. D., A. T. van Oosterom, C. R. Garrett, M. E. Blackstein, M. H. Shah, J. Verweij, G. McArthur, I. R. Judson, M. C. Heinrich, J. A. Morgan, J. Desai, C. D. Fletcher, S. George, C. L. Bello, X. Huang, C. M. Baum & P. G. Casali: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 368, 1329-38 (2006). (Pubitemid 44528723)
43. Zhou, Q., P. Guo & J. M. Gallo: Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res, 14, 1540-9 (2008). (Pubitemid 351413939)
44. Hecht, J. R., T. Trarbach, E. Jaeger, J. Hainsworth, R. Wolff, K. Lloyd, G. Bodoky, M. Borner, D. Laurent & C. Jacques: A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol (Meeting Abstracts), 23, LBA3 (2005).
45. Kohne, C., E. Bajetta, E. Lin, J. W. Valle, E. Van Cutsem, J. R. Hecht, M. Moore, C. J. Germond, G. Meinhardt & C. Jacques: Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol (Meeting Abstracts), 25, 4033 (2007).
46. Major, P., T. Trarbach, H. Lenz, D. Kerr, K. Pendergrass, J. Douillard, B. Chen, D. Laurent, C. Jacques & E. van Cutsem: A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. J Clin Oncol (Meeting Abstracts), 24, 3529 (2006).
47. Azad, N. S., C. Annunziata, T. Barrett, C. Chen, S. Steinberg, V. E. Kwitkowski, D. McNally, H. Kotz, L. Minasian & E. C. Kohn: Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results. J Clin Oncol (Meeting Abstracts), 25, 3542 (2007).
48. Feldman, D. R., G. V. Kondagunta, E. A. Ronnen, P. Fischer, R. Chang, M. Baum, M. S. Ginsberg, N. Ishill, S. Patil & R. J. Motzer: Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts), 25, 5099 (2007).
49. Van Cruijsen, H., E. E. Voest, C. M. Van Herpen, K. Hoekman, P. O. Witteveen, A. t. Tjin, C. J. Punt, T. Puchalski, T. Milenkova & G. Giaccone: Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol (Meeting Abstracts), 24, 3017 (2006).
50. Dejonge, M., S. Savage, J. Verweij, T. S. Collins, F. Eskens, B. Whitehead, A. B. Suttle, L. B. Pandite, P. T. Ho & H. Hurwitz: A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol (Meeting Abstracts), 24, 3088 (2006).
51. Patel, P. H., G. V. Kondagunta, B. G. Redman, G. R. Hudes, S. T. Kim, I. Chen & R. J. Motzer: Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts), 25, 5097 (2007).
52. Speca, J. C., A. L. Mears, P. A. Creel, S. E. Yenser, J. C. Bendell, M. A. Morse, H. I. Hurwitz, A. J. Armstrong & D. J. George: Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol (Meeting Abstracts), 25, 5039 (2007).
53. Gollob, J. A., W. K. Rathmell, T. M. Richmond, C. B. Marino, E. K. Miller, G. Grigson, C. Watkins, L. Gu, B. L. Peterson & J. J. Wright: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol, 25, 3288-95 (2007). (Pubitemid 47325614)
54. Ryan, C. W., B. H. Goldman, P. N. Lara, Jr., P. C. Mack, T. M. Beer, C. M. Tangen, D. Lemmon, C. X. Pan, H. A. Drabkin & E. D. Crawford: Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol, 25, 3296-301 (2007). (Pubitemid 47325615)
55. Nordsmark, M. & J. Overgaard: A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology, 57, 39-43 (2000).
56. Dings, R. P., B. W. Williams, C. W. Song, A. W. Griffioen, K. H. Mayo & R. J. Griffin: Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer, 115, 312-9 (2005). (Pubitemid 40586743)
57. Fenton, B. M. & S. F. Paoni: The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res, 67, 9921-8 (2007). (Pubitemid 47621241)
58. Senan, S. & E. F. Smit: Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist, 12, 465-77 (2007). (Pubitemid 46698724)
59. Gupta, V. K., N. T. Jaskowiak, M. A. Beckett, H. J. Mauceri, J. Grunstein, R. S. Johnson, D. A. Calvin, E. Nodzenski, M. Pejovic, D. W. Kufe, M. C. Posner & R. R. Weichselbaum: Vascular endothelial growth factorenhances endothelial cell survival and tumor radioresistance. Cancer J, 8, 47-54 (2002).
60. Kumar, P., A. I. Miller & P. J. Polverini: p38 MAPK mediates {gamma}-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem, 279, 43352-60 (2004). (Pubitemid 39372230)
61. Sullivan, R. & C. H. Graham: Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev, 26, 319-31 (2007). (Pubitemid 47101665)
62. Casanovas, O., D. J. Hicklin, G. Bergers & D. Hanahan: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 8, 299-309 (2005). (Pubitemid 41443415)
63. Chang, Y. S., J. Adnane, P. A. Trail, J. Levy, A. Henderson, D. Xue, E. Bortolon, M. Ichetovkin, C. Chen, A. McNabola, D. Wilkie, C. A. Carter, I. C. Taylor, M. Lynch & S. Wilhelm: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol, 59, 561-74 (2007). (Pubitemid 46295136)
64. Lee, C. G., M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K. R. Park, N. Ferrara, R. K. Jain, H. D. Suit & Y. Boucher: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res, 60, 5565-70 (2000).
65. Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A. T. van Oosterom, M. C. Christian & S. G. Gwyther: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92, 205-16 (2000). (Pubitemid 30099779)
66. Faivre, S. J., E. Raymond, J. Douillard, E. Boucher, H. Y. Lim, J. S. Kim, S. Lanzalone, M. J. Lechuga, L. Sherman & A. Cheng: Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts), 25, 3546 (2007).
67. Flaherty, K. T. Sorafenib in renal cell carcinoma. Clin Cancer Res, 13, 747s-52s (2007).
68. Van der Veldt, A. A., M. R. Meijerink, A. J. van den Eertwegh, A. Bex, G. de Gast, J. B. Haanen & E. Boven: Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin.Cancer Res, in press (2008).
69. Azad, N. S., C. M. Annunziata, S. M. Steinberg, L. Minasian, A. Premkumar, C. Chow, H. L. Kotz & E. C. Kohn: Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer, 112, 1726-32 (2008). (Pubitemid 351536832)
70. Benjamin, R. S., H. Choi, H. A. Macapinlac, M. A. Burgess, S. R. Patel, L. L. Chen, D. A. Podoloff & C. Charnsangavej: We should desist using RECIST, at least in GIST. J Clin Oncol, 25, 1760-4 (2007). (Pubitemid 46797958)
71. Choi, H., C. Charnsangavej, S. C. Faria, H. A. Macapinlac, M. A. Burgess, S. R. Patel, L. L. Chen, D. A. Podoloff & R. S. Benjamin: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 25, 1753-9 (2007). (Pubitemid 46797957)
72. Rehman, S. & G. C. Jayson: Molecular imaging of antiangiogenic agents. Oncologist, 10, 92-103 (2005). (Pubitemid 40261948)
73. Flaherty, K. T., M. A. Rosen, D. F. Heitjan, M. L. Gallagher, B. Schwartz, M. D. Schnall & O. D. Pj: Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther, 7, (2008).
74. Liu, G., H. S. Rugo, G. Wilding, T. M. McShane, J. L. Evelhoch, C. Ng, E. Jackson, F. Kelcz, B. M. Yeh, F. T. Lee, Jr., C. Charnsangavej, J. W. Park, E. A. Ashton, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich & R. S. Herbst: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol, 23, 5464-73 (2005).
75. Morgan, B., A. L. Thomas, J. Drevs, J. Hennig, M. Buchert, A. Jivan, M. A. Horsfield, K. Mross, H. A. Ball, L. Lee, W. Mietlowski, S. Fuxius, C. Unger, K. O'Byrne, A. Henry, G. R. Cherryman, D. Laurent, M. Dugan, D. Marme & W. P. Steward: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol, 21, 3955-64 (2003). (Pubitemid 46606209)
76. Meijerink, M. R., H. van Cruijsen, K. Hoekman, M. Kater, C. van Schaik, J. H. van Waesberghe, G. Giaccone & R. A. Manoliu: The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol, 17, 1700-13 (2007). (Pubitemid 46909659)
77. Escudier, B., N. Lassau, E. Angevin, J. C. Soria, L. Chami, M. Lamuraglia, E. Zafarana, V. Landreau, B. Schwartz, E. Brendel, J. P. Armand & C. Robert: Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res, 13, 1801-9 (2007). (Pubitemid 46952949)
78. Lamuraglia, M., B. Escudier, L. Chami, B. Schwartz, J. Leclere, A. Roche & N. Lassau: To predict progressionfree survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer, 42, 2472-9 (2006). (Pubitemid 44442955)
79. Kelloff, G. J., J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'shaughnessy, K. Z. Guyton, D. A. Mankoff, L. Shankar, S. M. Larson, C. C. Sigman, R. L. Schilsky & D. C. Sullivan: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res, 11, 2785-808 (2005). (Pubitemid 40525178)
80. Jennens, R. R., M. A. Rosenthal, G. J. Lindeman & M. Michael: Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urologic Oncology: Seminars and Original Investigations, 22, 193-6 (2004). (Pubitemid 38950624)
81. Anderson, H. & P. Price: Clinical measurement of blood flow in tumours using positron emission tomography: a review. Nucl Med Commun, 23, 131-8 (2002). (Pubitemid 34547900)
82. Wang, J. Q., K. D. Miller, G. W. Sledge & Q. H. Zheng: Synthesis of (18F)SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorganic & Medicinal Chemistry Letters, 15, 4380-4 (2005). (Pubitemid 41199807)
83. Chowdhury SJHP. Hypertension an targeted therapy. Part 1: Bevacizumab. Targeted Oncol, 104-8 (2006).
84. Chowdhury SJHP. Hypertension an targeted therapy. Part 2: Small molecule inhibitors of VEGF. Targeted Oncol, 1, 172-8 (2006).
85. Wu, S., J. J. Chen, A. Kudelka, J. Lu & X. Zhu: Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol, 9, 117-23 (2008).
86. Mourad, J. J., G. G. des, H. Debbabi & B. I. Levy: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol, (2007).
87. Li, B., A. K. Ogasawara, R. Yang, W. Wei, G. W. He, T. F. Zioncheck, S. Bunting, A. M. de Vos & H. Jin: KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension, 39, 1095-100 (2002). (Pubitemid 34620130)
88. Dimmeler, S., I. Fleming, B. Fisslthaler, C. Hermann, R. Busse & A. M. Zeiher: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399, 601-5 (1999).
89. Fulton, D., J. P. Gratton, T. J. Mccabe, J. Fontana, Y. Fujio, K. Walsh, T. F. Franke, A. Papapetropoulos & W. C. Sessa: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 399, 597-601 (1999).
90. He, H., V. J. Venema, X. Gu, R. C. Venema, M. B. Marrero & R. B. Caldwell: Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem, 274, 25130-5 (1999).
91. Kroll, J. & J. Waltenberger: VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun, 252, 743-6 (1998). (Pubitemid 28556847)
92. Scotland, R. S., M. Morales-Ruiz, Y. Chen, J. Yu, R. D. Rudic, D. Fulton, J. P. Gratton & W. C. Sessa: Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res, 90, 904-10 (2002). (Pubitemid 34633883)
93. Potenza, M. A., F. L. Marasciulo, D. M. Chieppa, G. S. Brigiani, G. Formoso, M. J. Quon & M. Montagnani: Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol, 289, H813-H822 (2005). (Pubitemid 41129399)
94. Jin, Z. G., H. Ueba, T. Tanimoto, A. O. Lungu, M. D. Frame & B. C. Berk: Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res, 93, 354-63 (2003). (Pubitemid 37048248)
95. Dirix, L. Y., H. Maes & C. Sweldens: Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol, 18, 1121-2 (2007). (Pubitemid 47050509)
96. Azizi, M., A. Chedid & S. Oudard: Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med, 358, 95-7 (2008).
97. Rixe, O., B. Billemont & H. Izzedine: Hypertension as a predictive factor of Sunitinib activity. Ann Oncol, 18, 1117 (2007). (Pubitemid 47050505)
98. van Heeckeren, W. J., J. Ortiz, M. M. Cooney & S. C. Remick: Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol, 25, 2993-5 (2007). (Pubitemid 47218042)
99. Zhu, X., S. Wu, W. L. Dahut & C. R. Parikh: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis, 49, 186-93 (2007). (Pubitemid 46178407)
100. Patel, T. V., J. A. Morgan, G. D. Demetri, S. George, R. G. Maki, M. Quigley & B. D. Humphreys: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst, 100, 282-4 (2008). (Pubitemid 351480534)
101. Eskens, F. A., A. Planting, L. Van Doorn, T. Isoe, K. Hayashi, S. Hussain, L. Ekman, H. Burger & J. Verweij: An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 24, 2034 (2006).
102. Rosen, L. S., R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, C. Ng, J. Silverman, A. Koutsoukos, Y. N. Sun, M. B. Bass, R. Y. Xu, A. Polverino, J. S. Wiezorek, D. D. Chang, R. Benjamin & R. S. Herbst: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol, 25, 2369-76 (2007). (Pubitemid 46999207)
103. Eremina, V., M. Sood, J. Haigh, A. Nagy, G. Lajoie, N. Ferrara, H. P. Gerber, Y. Kikkawa, J. H. Miner & S. E. Quaggin: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest, 111, 707-16 (2003). (Pubitemid 36278589)
104. Schmidinger, M., U. M. Vogl, C. Schukro, A. Bojic, M. Bojic, H. Schmidinger & C. C. Zielinski: Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts), 25, 5110 (2007).
105. Fiedler, W., H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A. M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, S. G. Louie, W. Hong, N. M. Brega, G. Massimini, P. Scigalla, W. E. Berdel & D. K. Hossfeld: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 105, 986-93 (2005). (Pubitemid 40170865)
106. Machiels, J. P., N. Bletard, P. Pirenne, L. Jacquet, F. Bonbled & L. Duck: Acute cardiac failure after sunitinib. Ann Oncol, 19, 597-9 (2008).
107. Chu, T. F., M. A. Rupnick, R. Kerkela, S. M. Dallabrida, D. Zurakowski, L. Nguyen, K. Woulfe, E. Pravda, F. Cassiola, J. Desai, S. George, J. A. Morgan, D. M. Harris, N. S. Ismail, J. H. Chen, F. J. Schoen, A. D. van den Abbeele, G. D. Demetri, T. Force & M. H. Chen: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 370, 2011-9 (2007). (Pubitemid 350236338)
108. Khakoo, A. Y., C. M. Kassiotis, N. Tannir, J. C. Plana, M. Halushka, C. Bickford, J. Trent, J. C. Champion, J. B. Durand & D. J. Lenihan: Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer, 112, 2500-9 (2008).
109. Mego, M., M. Reckova, J. Obertova, Z. Sycova-Mila, K. Brozmanova & J. Mardiak: Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol, 18, 1906-7 (2007). (Pubitemid 350111579)
110. Desai, J., L. Yassa, E. Marqusee, S. George, M. C. Frates, M. H. Chen, J. A. Morgan, S. S. Dychter, P. R. Larsen, G. D. Demetri & E. K. Alexander: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med, 145, 660-4 (2006). (Pubitemid 46768841)
111. Wolter, P., H. Dumez & P. Schoffski: Sunitinib and hypothyroidism. N Engl J Med, 356, 1580-1 (2007).
112. Wong, E., L. S. Rosen, M. Mulay, A. Vanvugt, M. Dinolfo, C. Tomoda, M. Sugawara & J. M. Hershman: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid, 17, 351-5 (2007). (Pubitemid 46776140)
113. Rini, B. I., I. Tamaskar, P. Shaheen, R. Salas, J. Garcia, L. Wood, S. Reddy, R. Dreicer & R. M. Bukowski: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 99, 81-3 (2007).
114. Tamaskar, I. R., J. Unnithan, J. A. Garcia, R. Dreicer, L. Wood, A. Iochimescu, R. Bukowski & B. Rini: Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. J Clin Oncol (Meeting Abstracts), 25, 5048 (2007).
115. Drevs, J., P. Siegert, M. Medinger, K. Mross, R. Strecker, U. Zirrgiebel, J. Harder, H. Blum, J. Robertson, J. M. Jurgensmeier, T. A. Puchalski, H. Young, O. Saunders & C. Unger: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol, 25, 3045-54 (2007). (Pubitemid 47218051)
116. Grossmann, M., E. Premaratne, J. Desai & I. D. Davis: Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf), Epub (2008).
117. Imada, M., M. Kurosumi & H. Fujita: Three-dimensional aspects of blood vessels in thyroids from normal, low iodine diet-treated, TSH-treated, and PTU-treated rats. Cell Tissue Res, 245, 291-6 (1986). (Pubitemid 16059011)
118. Viglietto, G., A. Romano, G. Manzo, G. Chiappetta, I. Paoletti, D. Califano, M. G. Galati, V. Mauriello, P. Bruni, C. T. Lago, A. Fusco & M. G. Persico: Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene, 15, 2687-98 (1997). (Pubitemid 27507616)
119. Kamba, T., B. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, K. D. Anderson, G. Thurston, S. Joho, M. L. Springer, C. J. Kuo & D. M. McDonald: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 290, H560-H576 (2006).
120. Suzuki, K., A. Mori, J. Saito, E. Moriyama, L. Ullianich & L. D. Kohn: Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene. Endocrinology, 140, 5422-30 (1999).
121. Mannavola, D., P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto, P. Casari, P. Beck-Peccoz & L. Fugazzola: A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab, 92, 3531-4 (2007). (Pubitemid 47435331)
122. Rugo, H. S., R. S. Herbst, G. Liu, J. W. Park, M. S. Kies, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich, J. L. Freddo & G. Wilding: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol, 23, 5474-83 (2005).
123. Hedbom, S., S. Steinbild, A. Frost, M. Buchert, C. Unger, O. Christensen, M. Kornacker, D. Voliotis, R. Heinig & K. Mross: Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 25, 3593 (2007).
124. van Herpen, C., J. Drevs, H. van Cruijsen, E. E. Voest, C. J. Punt, J. Robertson, O. Saunders, U. Zirrgiebel, C. Unger & G. Giaccone: Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies. J Clin Oncol (Meeting Abstracts), 25, 3560 (2007).
125. Basson, M. D. Gut mucosal healing: is the science relevant? Am J Pathol, 161, 1101-5 (2002).
126. Cannistra, S. A., U. Matulonis, R. Penson, R. Wenham, D. Armstrong, R. A. Burger, H. Mackey, J. Douglas, J. Hambleton & W. McGuire: Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol (Meeting Abstracts), 24, 5006 (2006).
127. Friberg, G., A. M. Oza, R. J. Morgan, E. E. Vokes, D. R. Gandara & G. F. Fleming: Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial. J Clin Oncol (Meeting Abstracts), 24, 5018 (2006).
128. Scappaticci, F. A., L. Fehrenbacher, T. Cartwright, J. D. Hainsworth, W. Heim, J. Berlin, F. Kabbinavar, W. Novotny, S. Sarkar & H. Hurwitz: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol, 91, 173-80 (2005). (Pubitemid 41254420)
129. Heinzerling, J. H. & S. Huerta: Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Current Surgery, 63, 334-7 (2006). (Pubitemid 44340939)
130. Kozin, S. V., Y. Boucher, D. J. Hicklin, P. Bohlen, R. K. Jain & H. D. Suit: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res, 61, 39-44 (2001). (Pubitemid 32095696)
131. Lordick, F., H. Geinitz, J. Theisen, A. Sendler & M. Sarbia: Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys, 64, 1295-8 (2006).
132. Faivre, S., C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, J. P. Armand, P. Scigalla & E. Raymond: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 24, 25-35 (2006). (Pubitemid 46630490)
133. Dasanu, C. A., D. T. Alexandrescu & J. Dutcher: Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J, 100, 328-30 (2007). (Pubitemid 46673440)
134. Robert, C., J. C. Soria, A. Spatz, A. Le Cesne, D. Malka, P. Pautier, J. Wechsler, C. Lhomme, B. Escudier, V. Boige, J. P. Armand & T. Le Chevalier: Cutaneous sideeffects of kinase inhibitors and blocking antibodies. The Lancet Oncology, 6, 491-500 (2005). (Pubitemid 40903630)
135. Routhouska, S., A. C. Gilliam & P. Mirmirani: Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol, 142, 1477-9 (2006). (Pubitemid 44790642)
136. Moss, K. G., G. C. Toner, J. M. Cherrington, D. B. Mendel & A. D. Laird: Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther, 307, 476-80 (2003). (Pubitemid 37310659)
137. Roman, C. D., H. Choy, L. Nanney, C. Riordan, K. Parman, D. Johnson & R. D. Beauchamp: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res, 105, 43-7 (2002). (Pubitemid 34713210)
138. Howdieshell, T. R., D. Callaway, W. L. Webb, M. D. Gaines, C. D. Procter, Jr., Sathyanarayana, J. S. Pollock, T. L. Brock & P. L. McNeil: Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res, 96, 173-82 (2001). (Pubitemid 34969430)
139. Thornton, A. D., P. Ravn, M. Winslet & K. Chester: Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg, 93, 1456-63 (2006). (Pubitemid 44893645)
140. D'Angelica, M., P. Kornprat, M. Gonen, K. Y. Chung, W. R. Jarnagin, R. P. DeMatteo, Y. Fong, N. Kemeny, L. H. Blumgart & L. B. Saltz: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol, 14, 759-65 (2007). (Pubitemid 46175324)
141. Duan, W. R., S. Patyna, M. A. Kuhlmann, S. Li & E. A. Blomme: A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. J Invest Surg, 19, 245-54 (2006). (Pubitemid 44103000)
142. Ko, J., J. Ross, H. Awad, H. Hurwitz & B. Klitzman: The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res, 129, 251-9 (2005). (Pubitemid 41797060)
143. Wood, J. M., G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O'Reilly, E. Persohn, J. Rosel, C. Schnell, D. Stover, A. Theuer, H. Towbin, F. Wenger, K. Woods-Cook, A. Menrad, G. Siemeister, M. Schirner, K. H. Thierauch, M. R. Schneider, J. Drevs, G. Martiny-Baron & F. Totzke: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res, 60, 2178-89 (2000). (Pubitemid 30225181)
144. Sandler, A., R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilenbaum & D. H. Johnson: Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med, 355, 2542-50 (2006). (Pubitemid 44917502)
145. Johnson, D. H., L. Fehrenbacher, W. F. Novotny, R. S. Herbst, J. J. Nemunaitis, D. M. Jablons, C. J. Langer, R. F. DeVore, III, J. Gaudreault, L. A. Damico, E. Holmgren & F. Kabbinavar: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 22, 2184-91 (2004). (Pubitemid 41095154)
146. Cohen, M. H., J. Gootenberg, P. Keegan & R. Pazdur: FDA drug approval summary: bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 12, 713-8 (2007). (Pubitemid 47036205)
147. Gauler, T. C., B. Besse, J. B. Meric, V. Gounant, B. Fischer, T. Overbeck, H. Krissel, D. Laurent, J. C. Soria & W. E. Eberhardt: Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1, 250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts), 25, 7541 (2007).
148. Kuenen, B. C., L. Rosen, E. F. Smit, M. R. Parson, M. Levi, R. Ruijter, H. Huisman, M. A. Kedde, P. Noordhuis, W. J. van der Vijgh, G. J. Peters, G. F. Cropp, P. Scigalla, K. Hoekman, H. M. Pinedo & G. Giaccone: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol, 20, 1657-67 (2002). (Pubitemid 34260548)
149. Zucker, S., H. Mirza, C. E. Conner, A. F. Lorenz, M. H. Drews, W. F. Bahou & J. Jesty: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer, 75, 780-6 (1998). (Pubitemid 28145828)
150. Bombeli, T., A. Karsan, J. F. Tait & J. M. Harlan: Apoptotic vascular endothelial cells become procoagulant. Blood, 89, 2429-42 (1997). (Pubitemid 27143290)
151. Kuenen, B. C., M. Levi, J. C. Meijers, A. K. Kakkar, V. W. van Hinsbergh, P. J. Kostense, H. M. Pinedo & K. Hoekman: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol, 22, 1500-5 (2002).
152. Togna, G. I., A. R. Togna, M. Franconi & L. Caprino: Cisplatin triggers platelet activation. Thromb Res, 99, 503-9 (2000).
153. Scappaticci, F. A., J. R. Skillings, S. N. Holden, H. P. Gerber, K. Miller, F. Kabbinavar, E. Bergsland, J. Ngai, E. Holmgren, J. Wang & H. Hurwitz: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 99, 1232-9 (2007). (Pubitemid 47299901)
154. Lonial, S., M. Alsina, K. C. Anderson, P. Richardson, K. Stewart, R. Fonseca, C. Heise, J. Fox, A. Allen & G. Michelson: Phase I trial of chir-258 in multiple myeloma. J Clin Oncol (Meeting Abstracts), 24, 17502 (2006).
155. Strumberg, D., H. Richly, R. A. Hilger, N. Schleucher, S. Korfee, M. Tewes, M. Faghih, E. Brendel, D. Voliotis, C. G. Haase, B. Schwartz, A. Awada, R. Voigtmann, M. E. Scheulen & S. Seeber: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23, 965-72 (2005). (Pubitemid 46202316)
156. Banu, N., B. Deng, S. D. Lyman & H. Avraham: Modulation of haematopoietic progenitor development by FLT-3 ligand. Cytokine, 11, 679-88 (1999). (Pubitemid 29428001)
157. Leong, S. A phase I study of sunitinib in combination with modified FOLFOX 6 (mFOLFOX6) chemotherapy. Gastrointestinal Cancers Symposium (2007).
158. Tam, B. Y., K. Wei, J. S. Rudge, J. Hoffman, J. Holash, S. K. Park, J. Yuan, C. Hefner, C. Chartier, J. S. Lee, S. Jiang, N. R. Niyak, F. A. Kuypers, L. Ma, U. Sundram, G. Wu, J. A. Garcia, S. L. Schrier, J. J. Maher, R. S. Johnson, G. D. Yancopoulos, R. C. Mulligan & C. J. Kuo: VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med, 12, 793-800 (2006). (Pubitemid 44050069)
159. Fischer, C., P. Carmeliet & E. M. Conway: VEGF inhibitors make blood. Nat Med, 12, 732-4 (2006). (Pubitemid 44050049)
160. Govindarajan, R., J. Adusumilli, D. L. Baxter, A. El Khoueiry & S. I. Harik: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol, 24, e48 (2006).
161. Kapiteijn, E., A. Brand, J. Kroep & H. Gelderblom: Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol, 18, 1745-7 (2007). (Pubitemid 47506266)
162. Martin, G., L. Bellido & J. J. Cruz: Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol, 25, 3559 (2007). (Pubitemid 47310905)
163. Allen, J. A., A. Adlakha & P. R. Bergethon: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol, 63, 1475-8 (2006). (Pubitemid 44547561)
164. Glusker, P., L. Recht & B. Lane: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med, 354, 980-2 (2006).
165. Lambrechts, D. & P. Carmeliet: VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta, 1762, 1109-21 (2006). (Pubitemid 44781175)
166. Van der Veldt, A. A., A. J. van den Eertwegh, K. Hoekman, F. Barkhof & E. Boven: Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol, 18, 1747-50 (2007). (Pubitemid 47506267)
167. Thomas, A. L., B. Morgan, M. A. Horsfield, A. Higginson, A. Kay, L. Lee, E. Masson, M. Puccio-Pick, D. Laurent & W. P. Steward: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol, 23, 4162-71 (2005). (Pubitemid 46211322)
168. Helgason, H. H., H. A. Mallo, H. Droogendijk, J. Haanen, A. A. M. van der Veldt, A. J. van den Eertwegh & E. Boven: Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol, 26, 152-4 (2008).
169. Koutras, A. K., D. Krikelis, N. Alexandrou, I. Starakis & H. P. Kalofonos: Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res, 27, 4255-7 (2007).
170. Massard, C., J. Zonierek, A. Laplanche, B. Schwartz, C. Szczylik & B. Escudier: Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral, multi-kinase inhibitor. Ann Oncol, 17, ix144-ix157 (2006).
171. Medioni, J., O. Cojocarasu, J. L. Belcaceres, P. Halimi & S. Oudard: Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol, 18, 1282-3 (2007). (Pubitemid 47244377)
172. Cordon-Cardo, C., J. P. O'Brien, J. Boccia, D. Casals, J. R. Bertino & M. R. Melamed: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem, 38, 1277-87 (1990). (Pubitemid 20266126)
173. Houk, B. E., C. L. Bello, M. D. Michaelson, R. M. Bukowski, B. G. Redman, G. R. Hudes, G. Wilding & R. J. Motzer: Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol (Meeting Abstracts), 25, 5027 (2007).
174. Li, J., M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo & S. D. Baker: CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst, 98, 1714-23 (2006). (Pubitemid 44942709)
175. Adjei, A. A., S. Mandrekar, R. S. Marks, L. J. Hanson, D. Aranguren, J. R. Jett, R. Simantov, B. Schwartz & G. A. Croghan: A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts), 23, 3067 (2005).
176. Mancuso, M. R., R. Davis, S. M. Norberg, S. O'Brien, B. Sennino, T. Nakahara, V. J. Yao, T. Inai, P. Brooks, B. Freimark, D. R. Shalinsky, D. D. Hu-Lowe & D. M. McDonald: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest, 116, 2610-21 (2006). (Pubitemid 44511625)
177. Jain, R. K., R. T. Tong & L. L. Munn: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res, 67, 2729-35 (2007). (Pubitemid 46548961)
178. Norden-Zfoni, A., J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, D. R. Shalinsky, G. D. Demetri & J. V. Heymach: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res, 13, 2643-50 (2007). (Pubitemid 46788031)
179. Traxler, P., P. R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, D. Fabbro, K. Grosios, H. A. Lane, P. McSheehy, J. Mestan, T. Meyer, C. Tang, M. Wartmann, J. Wood & G. Caravatti: AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res, 64, 4931-41 (2004). (Pubitemid 38924540)
180. Wong, C. I., C. H. Thng, R. Soo, C. S. Chen, N. Sukri, N. Gupta, E. McKeegan, S. C. Lee, R. Humerickhouse & B. C. Goh: Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol (Meeting Abstracts), 25, 3519 (2007).
181. Albert, D. H., P. Tapang, T. J. Magoc, L. J. Pease, D. R. Reuter, R. Q. Wei, J. Li, J. Guo, P. F. Bousquet, N. S. Ghoreishi-Haack, B. Wang, G. T. Bukofzer, Y. C. Wang, J. A. Stavropoulos, K. Hartandi, A. L. Niquette, N. Soni, E. F. Johnson, J. O. McCall, J. J. Bouska, Y. Luo, C. K. Donawho, Y. Dai, P. A. Marcotte, K. B. Glaser, M. R. Michaelides & S. K. Davidsen: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther, 5, 995-1006 (2006). (Pubitemid 43724600)
182. Rini, B. I., G. T. Wilding, G. Hudes, W. M. Stadler, S. Kim, J. C. Tarazi, P. W. Bycott, K. F. Liau & J. P. Dutcher: Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol (Meeting Abstracts), 25, 5032 (2007).
183. Wedge, S. R., J. Kendrew, L. F. Hennequin, P. J. Valentine, S. T. Barry, S. R. Brave, N. R. Smith, N. H. James, M. Dukes, J. O. Curwen, R. Chester, J. A. Jackson, S. J. Boffey, L. L. Kilburn, S. Barnett, G. H. P. Richmond, P. F. Wadsworth, M. Walker, A. L. Bigley, S. T. Taylor, L. Cooper, S. Beck, J. M. Jurgensmeier & D. J. Ogilvie: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 65, 4389-400 (2005). (Pubitemid 40775678)
184. Miller, K. D., J. M. Trigo, C. Wheeler, A. Barge, J. Rowbottom, G. Sledge & J. Baselga: A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res, 11, 3369-76 (2005). (Pubitemid 40627889)
185. Wedge, S. R., D. J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J. A. Jackson, S. J. Boffey, P. J. Valentine, J. O. Curwen, H. L. Musgrove, G. A. Graham, G. D. Hughes, A. P. Thomas, E. S. E. Stokes, B. Curry, G. H. P. Richmond, P. F. Wadsworth, A. L. Bigley & L. F. Hennequin: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res, 62, 4645-55 (2002).
186. Carlomagno, F., S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm & M. Santoro: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98, 326-34 (2006). (Pubitemid 43338212)
187. Wilhelm, S. M., C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L. E. Post, G. Bollag & P. A. Trail: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109 (2004). (Pubitemid 39331023)
188. Gelderblom, H., J. Verweij, N. Steeghs, A. Van Erkel, L. Van Doorn, J. Ouwerkerk, P. Rajagopalan, A. Matthys, D. Voliotis & F. Eskens: Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 24, 3040 (2006).
189. Lee, C. P., G. Attard, L. Poupard, P. D. Nathan, J. S. De Bono, G. M. R. Temple, M. F. Stefanic, A. R. Padhani, I. R. Judson & G. J. Rustin: A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. J Clin Oncol (Meeting Abstracts), 23, 3054 (2005).
190. Lee, C. P., N. J. Taylor, G. Attard, P. D. Nathan, J. S. De Bono, G. Temple, A. Tang, A. R. Padhani, I. R. Judson & G. J. Rustin: A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol (Meeting Abstracts), 24, 3015 (2006).
191. Jonker, D. J., L. S. Rosen, M. Sawyer, G. Wilding, C. Noberasco, G. Jayson, G. Rustin, G. McArthur, L. Velasquez & S. Galbraith: A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol (Meeting Abstracts), 25, 3559 (2007).
192. Rosen, L. S., G. Wilding, C. Sweeney, D. Casale, G. Kollia, C. Wu, M. Ayers, C. Hill & S. M. Galbraith: Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol (Meeting Abstracts), 24, 3051 (2006).
193. Lee, S. H., D. Lopes de Menezes, J. Vora, A. Harris, H. Ye, L. Nordahl, E. Garrett, E. Samara, S. L. Aukerman, A. B. Gelb & C. Heise: In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res, 11, 3633-41 (2005). (Pubitemid 40685578)
194. Beebe, J. S., J. P. Jani, E. Knauth, P. Goodwin, C. Higdon, A. M. Rossi, E. Emerson, M. Finkelstein, E. Floyd, S. Harriman, J. Atherton, S. Hillerman, C. Soderstrom, K. Kou, T. Gant, M. C. Noe, B. Foster, F. Rastinejad, M. A. Marx, T. Schaeffer, P. M. Whalen & W. G. Roberts: Pharmacological characterization of CP-547, 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res, 63, 7301-9 (2003). (Pubitemid 37413471)
195. Cohen, R. B., C. J. Langer, G. R. Simon, P. D. Eisenberg, J. D. Hainsworth, S. Madajewicz, T. M. Cosgriff, K. Pierce, H. Xu, K. Liau & D. Healey: A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547, 632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as firstline treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol, 60, 81-9 (2007). (Pubitemid 46643721)
196. Glen, H., D. Boss, T. R. Evans, M. Roelvink, J. M. Saro, P. Bezodis, W. Copalu, A. Das, G. Crosswell & J. H. Schellens: A phase I dose finding study of E7080 in patients (pts) with advanced malignancies. J Clin Oncol (Meeting Abstracts), 25, 14073 (2007).
197. Hurwitz, H., A. Dowlati, S. Savage, N. Fernando, S. Lasalvia, B. Whitehead, B. Suttle, D. Collins, P. Ho & L. Pandite: Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol (Meeting Abstracts), 23, 3012 (2005).
198. Nakamura, K., E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, R. Suzuki, K. Kubo, M. Shibuya & T. Isae: KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res, 66, 9134-42 (2006). (Pubitemid 44521133)
199. Kim, D. W., Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, S. J. Lee, K. W. Jo & M. Shong: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab, 91, 4070-6 (2006). (Pubitemid 44536887)
200. Abrams, T. J., L. B. Lee, L. J. Murray, N. K. Pryer & J. M. Cherrington: SU11248 inhibits KIT and plateletderived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2, 471-8 (2003).
201. O'Farrell, A. M., T. J. Abrams, H. A. Yuen, T. J. Ngai, S. G. Louie, K. W. Yee, L. M. Wong, W. Hong, L. B. Lee, A. Town, B. D. Smolich, W. C. Manning, L. J. Murray, M. C. Heinrich & J. M. Cherrington: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 101, 3597-605 (2003). (Pubitemid 36857948)
202. Mendel, D. B., A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, R. E. Schreck, T. J. Abrams, T. J. Ngai, L. B. Lee, L. J. Murray, J. Carver, E. Chan, K. G. Moss, J. O. Haznedar, J. Sukbuntherng, R. A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon & J. M. Cherrington: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 9, 327-37 (2003). (Pubitemid 36109749)
203. Fiedler, W. M., G. Giaccone, P. Lasch, I. Van der Horst, N. M. Brega, S. Raber, D. Shalinsky, V. Ljubmir, C. Bokemeyer & E. Boven: Phase I trial of SU014813 in patients (pts) with advanced solid malignancies. J Clin Oncol (Meeting Abstracts), 25, 3521 (2007).
204. Patyna, S., A. D. Laird, D. B. Mendel, A. M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, M. Grazzini, C. Y. Yang, J. O. Haznedar, J. Sukbuntherng, W. Z. Zhong, J. M. Cherrington & D. Hu-Lowe: SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther, 5, 1774-82 (2006). (Pubitemid 44323245)
205. Wakelee, H. A., J. R. Molina, J. M. Fehling, J. L. Lensing & B. I. Sikic: A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies. J Clin Oncol (Meeting Abstracts), 25, 14044 (2007).
206. Cooper, J., M. M. Mita, J. Curtright, A. Ricart, A. Mita, C. Takimoto, A. Tolcher, A. Dowlati, S. Flick & K. P. Papadopoulos: A phase I study examining weekly dosing and pharmacokinetics (PK) of a novel spectrum selective kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM). J Clin Oncol (Meeting Abstracts), 24, 13024 (2006).